Reason for request
New indication
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of LIBTAYO (cemiplimab) in association with a platinum salt-based chemotherapy regimen, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
DYz4rXRZxV7TAqn5
